Sunnova Energy International
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2K
- Market Cap
- -
- Introduction
Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company’s goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs such as autism spectrum disorder (ASD) and FXS. It has one industry segment, being research and development of psilocybin, and in one geographic area, which is Canada.
An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome
Phase 2
Suspended
- Conditions
- Cognitive DysfunctionFragile X SyndromeBehavior
- Interventions
- Drug: Psilocybin, 1.5 mg
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Nova Mentis Life Science Corp
- Target Recruit Count
- 10
- Registration Number
- NCT05832255
- Locations
- 🇨🇦
KGK Science Inc., London, Ontario, Canada
Establishing a Diagnostic and Therapeutic Index in Autism Spectrum Disorder (ASD) and Fragile X Syndrome
- Conditions
- Fra(X) SyndromeAutism Spectrum Disorder
- Interventions
- Other: specimen collection
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Nova Mentis Life Science Corp
- Target Recruit Count
- 300
- Registration Number
- NCT04869930
- Locations
- 🇺🇸
Broward Health Medical Center, Fort Lauderdale, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath